1226P Predicting benefit from maintenance durvalumab after first-line chemotherapy (1L CTx) in oesophagogastric adenocarcinoma (OGA) using a novel tumour microenvironment (TME) RNA-based assay.
Saved in:
| Title: | 1226P Predicting benefit from maintenance durvalumab after first-line chemotherapy (1L CTx) in oesophagogastric adenocarcinoma (OGA) using a novel tumour microenvironment (TME) RNA-based assay. |
|---|---|
| Authors: | Fong, C.Y.K.1 (AUTHOR), Iyer, S.2 (AUTHOR), Potts, L.3 (AUTHOR), Peckitt, C.3 (AUTHOR), Cromarty, S.1 (AUTHOR), Saffery, C.1 (AUTHOR), Kidd, S.1 (AUTHOR), Rana, T.1 (AUTHOR), Ausec, L.4 (AUTHOR), Gregorc, A.4 (AUTHOR), Pointing, D.4 (AUTHOR), Gombert, M.5 (AUTHOR), von Loga, K.6 (AUTHOR), Benjamin, L.7 (AUTHOR), Starling, N.1 (AUTHOR), Waddell, T.S.8 (AUTHOR), Petty, R.9 (AUTHOR), Uhlik, M.2 (AUTHOR), Chau, I.1 (AUTHOR), Cunningham, D.1 (AUTHOR) |
| Source: | Annals of Oncology. 2022 Supplement 7, Vol. 33, pS1110-S1110. 1p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 159078127 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: 1226P Predicting benefit from maintenance durvalumab after first-line chemotherapy (1L CTx) in oesophagogastric adenocarcinoma (OGA) using a novel tumour microenvironment (TME) RNA-based assay. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Fong%2C+C%2EY%2EK%2E%22">Fong, C.Y.K.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Iyer%2C+S%2E%22">Iyer, S.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Potts%2C+L%2E%22">Potts, L.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Peckitt%2C+C%2E%22">Peckitt, C.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cromarty%2C+S%2E%22">Cromarty, S.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Saffery%2C+C%2E%22">Saffery, C.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kidd%2C+S%2E%22">Kidd, S.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Rana%2C+T%2E%22">Rana, T.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ausec%2C+L%2E%22">Ausec, L.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gregorc%2C+A%2E%22">Gregorc, A.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Pointing%2C+D%2E%22">Pointing, D.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gombert%2C+M%2E%22">Gombert, M.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22von+Loga%2C+K%2E%22">von Loga, K.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Benjamin%2C+L%2E%22">Benjamin, L.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Starling%2C+N%2E%22">Starling, N.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Waddell%2C+T%2ES%2E%22">Waddell, T.S.</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Petty%2C+R%2E%22">Petty, R.</searchLink><relatesTo>9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Uhlik%2C+M%2E%22">Uhlik, M.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Chau%2C+I%2E%22">Chau, I.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cunningham%2C+D%2E%22">Cunningham, D.</searchLink><relatesTo>1</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2022 Supplement 7, Vol. 33, pS1110-S1110. 1p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=159078127 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.annonc.2022.07.1344 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 1 StartPage: S1110 Titles: – TitleFull: 1226P Predicting benefit from maintenance durvalumab after first-line chemotherapy (1L CTx) in oesophagogastric adenocarcinoma (OGA) using a novel tumour microenvironment (TME) RNA-based assay. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Fong, C.Y.K. – PersonEntity: Name: NameFull: Iyer, S. – PersonEntity: Name: NameFull: Potts, L. – PersonEntity: Name: NameFull: Peckitt, C. – PersonEntity: Name: NameFull: Cromarty, S. – PersonEntity: Name: NameFull: Saffery, C. – PersonEntity: Name: NameFull: Kidd, S. – PersonEntity: Name: NameFull: Rana, T. – PersonEntity: Name: NameFull: Ausec, L. – PersonEntity: Name: NameFull: Gregorc, A. – PersonEntity: Name: NameFull: Pointing, D. – PersonEntity: Name: NameFull: Gombert, M. – PersonEntity: Name: NameFull: von Loga, K. – PersonEntity: Name: NameFull: Benjamin, L. – PersonEntity: Name: NameFull: Starling, N. – PersonEntity: Name: NameFull: Waddell, T.S. – PersonEntity: Name: NameFull: Petty, R. – PersonEntity: Name: NameFull: Uhlik, M. – PersonEntity: Name: NameFull: Chau, I. – PersonEntity: Name: NameFull: Cunningham, D. IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 09 Text: 2022 Supplement 7 Type: published Y: 2022 Identifiers: – Type: issn-print Value: 09237534 Numbering: – Type: volume Value: 33 Titles: – TitleFull: Annals of Oncology Type: main |
| ResultId | 1 |
